Optimizing lornoxicam-loaded poly(lactic-co-glycolic acid) and (polyethylene glycol) nanoparticles for transdermal delivery: ex vivo/in vivo inflammation evaluation.

Nanomedicine (London, England) Pub Date : 2024-07-02 DOI:10.1080/17435889.2024.2359356

Rubina Qaiser, Fahad Pervaiz, Sobia Noreen, Hanasul Hanan, Hina Shoukat, Hassan Mahmood, Muhammad Azeem Ashraf

{"title":"Optimizing lornoxicam-loaded poly(lactic-co-glycolic acid) and (polyethylene glycol) nanoparticles for transdermal delivery: ex vivo/in vivo inflammation evaluation.","authors":"Rubina Qaiser, Fahad Pervaiz, Sobia Noreen, Hanasul Hanan, Hina Shoukat, Hassan Mahmood, Muhammad Azeem Ashraf","doi":"10.1080/17435889.2024.2359356","DOIUrl":null,"url":null,"abstract":"Aim: This study focused on developing a topical gel incorporating lornoxicam-loaded poly(lactic-co-glycolic acid) and polyethylene glycol (PLGA-PEG) blend nanoparticles to mitigate gastrointestinal (GIT) side effects and enhance therapeutic efficacy. Materials & methods: Synthesized nanoparticles were subjected to in vitro characterization, ex vivo permeation studies, and acute oral toxicity analysis post-incorporation into the gel using a S/O/W double emulsion solvent. Results & conclusion: The nanoparticles displayed a smooth, spherical morphology (170-321 nm) with increased entrapment efficiency (96.2%). LOX exhibited a permeation rate of 70-94% from the nanoparticle-infused gel, demonstrating favorable biocompatibility at the cellular level. The formulated gel, enriched with nanoparticles, holds promising prospects for drug-delivery systems and promising improved therapeutic outcomes for LOX.","PeriodicalId":74240,"journal":{"name":"Nanomedicine (London, England)","volume":" ","pages":"1471-1485"},"PeriodicalIF":0.0000,"publicationDate":"2024-07-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11318691/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nanomedicine (London, England)","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17435889.2024.2359356","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: This study focused on developing a topical gel incorporating lornoxicam-loaded poly(lactic-co-glycolic acid) and polyethylene glycol (PLGA-PEG) blend nanoparticles to mitigate gastrointestinal (GIT) side effects and enhance therapeutic efficacy. Materials & methods: Synthesized nanoparticles were subjected to in vitro characterization, ex vivo permeation studies, and acute oral toxicity analysis post-incorporation into the gel using a S/O/W double emulsion solvent. Results & conclusion: The nanoparticles displayed a smooth, spherical morphology (170-321 nm) with increased entrapment efficiency (96.2%). LOX exhibited a permeation rate of 70-94% from the nanoparticle-infused gel, demonstrating favorable biocompatibility at the cellular level. The formulated gel, enriched with nanoparticles, holds promising prospects for drug-delivery systems and promising improved therapeutic outcomes for LOX.

查看原文本刊更多论文

优化用于透皮给药的洛诺昔康负载聚（乳酸-共-乙醇酸）和（聚乙二醇）纳米颗粒：体内/体外炎症评估。

目的：本研究的重点是开发一种外用凝胶，其中含有洛诺昔康（lornoxicam）负载的聚（乳酸-共-乙醇酸）和聚乙二醇（PLGA-PEG）混合纳米粒子，以减轻胃肠道（GIT）副作用并提高疗效。材料与方法：使用 S/O/W 双乳液溶剂将合成的纳米颗粒加入凝胶后，进行体外表征、体内外渗透研究和急性口服毒性分析。结果与结论：纳米颗粒显示出光滑的球形形态（170-321 nm），并提高了吸附效率（96.2%）。注入纳米颗粒的凝胶中，LOX 的渗透率为 70-94%，显示出良好的细胞生物相容性。富含纳米颗粒的配制凝胶在药物输送系统中具有广阔的前景，有望改善对 LOX 的治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Nanomedicine (London, England)

自引率

0.00%

发文量